Mostrar el registro sencillo del ítem

dc.contributor.author
Jorge, Ricardo E.  
dc.contributor.author
Acion, Laura  
dc.contributor.author
Burin, Debora Ines  
dc.contributor.author
Robinson, Robert G.  
dc.date.available
2018-09-18T21:50:05Z  
dc.date.issued
2016-10  
dc.identifier.citation
Jorge, Ricardo E.; Acion, Laura; Burin, Debora Ines; Robinson, Robert G.; Sertraline for Preventing Mood Disorders Following Traumatic Brain InjuryA Randomized Clinical Trial; American Medical Association; JAMA Psychiatry; 73; 10; 10-2016; 1041-1047  
dc.identifier.issn
2168-622X  
dc.identifier.uri
http://hdl.handle.net/11336/60183  
dc.description.abstract
IMPORTANCE Prevention is more effective than treatment to decrease the burden of significant medical conditions such as depressive disorders, a major cause of disability worldwide. Traumatic brain injury (TBI) is a candidate for selective strategies to prevent depression given the incidence, prevalence, and functional effect of depression that occurs after TBI. OBJECTIVE To assess the efficacy of sertraline treatment in preventing depressive disorders following TBI. DESIGN, SETTING, AND PARTICIPANTS A double-blind, placebo-controlled, parallel-group randomized clinical trial was conducted at a university hospital from July 3, 2008, to September 17, 2012, with 24 weeks of follow-up. A consecutive sample of 534 patients aged 18 to 85 years, hospitalized for mild, moderate, or severe TBI, was eligible for the study. Ninety-four patients consented to participate and were randomized (46 to placebo and 48 to sertraline), of whom 79 (84%) completed the study. Intention-To-Treat data analysis was conducted from July 1, 2014, to December 31, 2015. INTERVENTIONS Placebo or sertraline, 100mg/d, for 24 weeks or until development of a mood disorder. MAIN OUTCOMES AND MEASURES Time to onset of depressive disorders, as defined by the DSM-IV, associated with TBI. RESULTS Of the 94 patients in the study (38 female and 56 male; 92 white), the number needed to treat to prevent depression after TBI at 24 weeks was 5.9 (95%CI, 3.1-71.1; x2 = 4.6; P = .03) for sertraline treatment vs placebo. The influence of sertraline in the course of neuropsychological variables was not detected. The intervention was well tolerated, and adverse effects were mild in both the sertraline and placebo groups. CONCLUSIONS AND RELEVANCE Sertraline appears to be efficacious to prevent the onset of depressive disorders following TBI. Future studies should replicate these findings in a large sample of patients with TBI and depict their long-Term physical, cognitive, behavioral, and functional outcomes.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
American Medical Association  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Prevention  
dc.subject
Mood Disorders  
dc.subject
Sertraline  
dc.subject
Traumatic Brain Injury  
dc.subject.classification
Medicina Critica y de Emergencia  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Sertraline for Preventing Mood Disorders Following Traumatic Brain InjuryA Randomized Clinical Trial  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2018-09-14T13:15:32Z  
dc.journal.volume
73  
dc.journal.number
10  
dc.journal.pagination
1041-1047  
dc.journal.pais
Estados Unidos  
dc.description.fil
Fil: Jorge, Ricardo E.. Baylor College Of Medicine; Estados Unidos  
dc.description.fil
Fil: Acion, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. University of Iowa; Estados Unidos. Baylor College Of Medicine; Estados Unidos  
dc.description.fil
Fil: Burin, Debora Ines. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Robinson, Robert G.. University of Iowa; Estados Unidos  
dc.journal.title
JAMA Psychiatry  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2548277  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1001/jamapsychiatry.2016.2189